HTBX - HTBX STOCK NEWS

Heat Biologics, Inc. (Nasdaq: HTBX) announced the acceptance of its latest data on HS-110 for poster presentation at the 2021 ASCO Annual Meeting, from June 4-8, 2021. The interim results focus on HS-110 combined with nivolumab in advanced non-small cell lung cancer (NSCLC) patients. Over 5,400 abstracts were reviewed for the conference. HS-110 is an allogeneic cell therapy designed for immune activation against tumor testis antigens, with positive interim survival data reported in specific treatment settings.

Heat Biologics (Nasdaq: HTBX) announced that PTX-35 will be featured during the 3rd Annual Treg Directed Therapies Summit on May 19-20, 2021. PTX-35, a first-in-class antibody targeting TNFRSF25, aims to expand regulatory T-cells and reduce disease severity in GVHD models. Presentations include discussions on enhancing outcomes of allo-HCT and exploring Treg behavior. PTX-35 is currently in a Phase 1 clinical trial for solid tumors. The company is also advancing other therapies via its gp96 platform, including HS-110 and a COVID-19 vaccine in preclinical stages.

Heat Biologics (Nasdaq: HTBX) announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor on May 10, 2021. Dr. Manning has over 30 years of experience in immunology and drug development, previously holding key positions at Momenta Pharmaceuticals and Biogen. His expertise is expected to enhance the strategic direction of Heat's product portfolio, which includes therapies aimed at cancer and infectious diseases, alongside a COVID-19 vaccine in development. CEO Jeff Wolf expressed confidence in Dr. Manning's ability to accelerate program development.

Heat Biologics (NASDAQ: HTBX) has provided updates for Q1 2021, reporting a net loss of $7.5 million, a rise from $6.3 million in the same quarter last year. The company recognized $0.5 million in grant revenue, down from $0.9 million. R&D expenses increased to $3.4 million, and general administrative expenses rose to $4.8 million. Despite these challenges, Heat maintains a robust balance sheet with over $128 million in cash and short-term investments, supporting ongoing clinical initiatives, including their COVID-19 vaccine and oncology programs.

Heat Biologics (HTBX) reported new preclinical data for PTX-35 at the AACR Annual Meeting 2021. PTX-35, currently in a Phase 1 trial for solid tumors, demonstrated decreased regulatory T-cell activity and enhanced CD4+ T cell effector responses in a mouse melanoma model. These findings suggest potential efficacy in overcoming cancer immune evasion. CEO Jeff Wolf expressed optimism about PTX-35's ability to activate the immune system. Interim clinical data is expected later this year.

Heat Biologics, Inc. (NASDAQ:HTBX) provided updates on financial, clinical, and operational performance for 2020. The company reported positive interim results from the Phase 2 trial of HS-110, showing a median overall survival of 24.6 months in advanced NSCLC patients. They are exploring Phase 3 pathways and initiated a Phase 1 trial for PTX-35. Heat Biologics also advanced its COVID-19 vaccine program using proprietary technology. As of year-end 2020, the company had $132 million in cash, with increased administrative expenses leading to a net loss of $26 million.

Heat Biologics, Inc. (NASDAQ:HTBX) has announced that CEO Jeff Wolf will present at the Inaugural Emerging Growth Virtual Conference from March 17-19, 2021, hosted by M Vest LLC and Maxim Group LLC. This presentation is accessible to registered participants and will later be available on the company's website. Heat Biologics focuses on developing immune-modulating therapies, including its gp96 platform targeting cancer and infectious diseases. Key projects include HS-110 in Phase 2 trials and a COVID-19 vaccine in preclinical development.

Heat Biologics (Nasdaq:HTBX) announced its participation in the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. The company specializes in developing therapies to enhance the immune system, with a focus on oncology and COVID-19 vaccines. Attendees can access Heat's presentation on-demand starting February 16th for 30 days. After the conference, the presentation will be available on Heat Biologics' investor relations website.

Heat's pipeline includes clinical trials for products like HS-110 and a COVID-19 vaccine.

Heat Biologics (NASDAQ:HTBX) announced positive interim results from its Phase 2 trial of HS-110 in combination with nivolumab for advanced non-small cell lung cancer (NSCLC). A median overall survival (OS) of 24.6 months and a one-year survival rate of 61.7% were observed in previously treated, checkpoint inhibitor naïve patients. Cohort B, with patients who experienced disease progression after checkpoint inhibitor therapy, showed a median OS of 11.9 months. The combination therapy demonstrated a favorable safety profile with no serious adverse reactions reported.